Persistent diarrhoea at 25. Blood in the stool at 30. Repeated abdominal pain, unexplained weight loss or an urgent need to find a toilet several times a day.

These symptoms are easy to blame on stress, irregular food habits or a “sensitive stomach.”

Sometimes, however, the problem is Inflammatory Bowel Disease (IBD).

IBD primarily includes ulcerative colitis and Crohn’s disease, two lifelong inflammatory conditions that damage the digestive tract. Importantly, these are not diseases restricted to older adults. CDC guidance notes that most people with IBD are diagnosed by age 30, and Indian registry data have also shown a peak age of onset in the third decade of life.

For a young adult who may be studying, beginning a career, travelling, getting married or planning a family, uncontrolled IBD can have a major impact on everyday life.

But the treatment landscape has also changed significantly.

Modern IBD treatment is increasingly focused not simply on reducing diarrhoea or abdominal pain, but on controlling inflammation, healing the intestine, preventing complications and maintaining long-term steroid-free remission.

What Exactly Is Inflammatory Bowel Disease?

IBD is a group of chronic inflammatory diseases affecting the digestive tract.

The two major forms are:

Ulcerative Colitis

Ulcerative colitis primarily affects the colon and rectum.

Common symptoms can include:

• Blood or mucus in the stool
• Frequent bowel movements
• Urgency to pass stool
• Abdominal cramping
• Diarrhoea

The inflammation involves the inner lining of the colon and can range from disease limited to the rectum to inflammation affecting much or all of the colon.

Crohn’s Disease

Crohn’s disease can affect any part of the digestive tract from the mouth to the anus, although the end of the small intestine and colon are commonly involved.

Unlike ulcerative colitis, inflammation in Crohn’s disease can extend deeper through the intestinal wall and occur in separated patches of the digestive tract.

Patients may develop:

• Persistent diarrhoea
• Abdominal pain
• Weight loss
• Poor nutrition
• Mouth ulcers
• Fatigue
• Perianal problems

More complicated Crohn’s disease can also cause narrowing of the bowel, obstruction, abscesses or fistulas.

Is IBD Becoming More Relevant in India?

Yes.

IBD was historically regarded as much more common in Western countries, but that picture has changed.

Indian research has documented a substantial and growing disease burden. A large Indian IBD registry found that ulcerative colitis was approximately twice as common as Crohn’s disease in the registry population, with peak disease onset occurring during the third decade of life.

More recent Indian research continues to describe increasing incidence and prevalence of IBD in the country.

This makes persistent inflammatory bowel symptoms in younger Indians increasingly important to investigate rather than automatically labelling them as IBS, food intolerance or stress.

Why Do Young Adults Develop IBD?

There is no single lifestyle habit that causes IBD.

The condition appears to result from a complicated interaction involving:

genetics + the immune system + gut microorganisms + environmental exposures.

The immune system becomes abnormally activated and contributes to persistent inflammation and injury within the digestive tract. More than 200 genetic variations have been associated with IBD susceptibility, although having these genes does not mean a person will definitely develop the condition.

This distinction is important because someone cannot simply “eat better” and expect established Crohn’s disease or ulcerative colitis to disappear.

Diet can be an important part of management, but IBD is a genuine inflammatory disease requiring appropriate medical evaluation.

IBD Is Not the Same as IBS

The abbreviations sound similar, but IBD and IBS are fundamentally different conditions.

IBS, or irritable bowel syndrome, can cause symptoms such as abdominal pain, bloating, diarrhoea or constipation.

However, IBS does not cause the intestinal inflammation and tissue damage seen in IBD.

That difference changes everything.

A patient with IBS may need dietary, lifestyle and symptom-based treatment.

A patient with active Crohn’s disease or ulcerative colitis may require anti-inflammatory medicines, immunomodulators, biologic therapy or other advanced treatment to prevent ongoing intestinal damage.

Symptoms Young Adults Should Not Keep Ignoring

Occasional diarrhoea after outside food is common.

IBD should become more concerning when symptoms are persistent, recurrent or accompanied by warning signs.

These can include:

• Diarrhoea continuing for several weeks
• Blood in the stool
• Mucus in the stool
• Persistent abdominal pain
• Frequent urgency to pass stool
• Night-time diarrhoea
• Unexplained weight loss
• Persistent tiredness
• Anaemia
• Fever
• Reduced appetite
• Repeated mouth ulcers
• Pain or discharge around the anus

IBD symptoms often fluctuate between flare-ups and periods of remission, which can make patients delay evaluation when symptoms temporarily improve.

IBD Can Affect More Than the Intestine

IBD is primarily a digestive disease, but the inflammatory process can also be associated with problems elsewhere in the body.

Patients may experience issues involving the joints, skin or eyes, while chronic intestinal inflammation and poor absorption can contribute to anaemia and nutritional deficiencies.

For young adults, the disease can also interfere with work, education, travel, relationships and psychological well-being. CDC resources recognise the substantial quality-of-life impact of IBD and the increased burden of anxiety and depression among affected patients.

Treating IBD therefore means more than controlling how many times someone goes to the bathroom.

How Is IBD Diagnosed?

There is no single blood test that can definitively diagnose Crohn’s disease or ulcerative colitis.

Diagnosis usually combines several pieces of information.

Blood Tests

Blood investigations may help detect:

• Anaemia
• Evidence of inflammation
• Nutritional problems
• Infection
• Other abnormalities

Blood tests help build the clinical picture but are not enough by themselves to confirm IBD.

Stool Tests

Stool testing may be used to exclude infection and identify evidence of intestinal inflammation.

One increasingly useful test is faecal calprotectin.

Calprotectin is released during intestinal inflammation and can help doctors distinguish inflammatory disease from non-inflammatory conditions in appropriate patients.

The updated 2025 ACG Crohn’s disease guideline specifically incorporates faecal calprotectin into diagnosis and monitoring strategies.

Colonoscopy and Biopsy

Colonoscopy is one of the most important investigations for suspected ulcerative colitis or Crohn’s disease involving the colon.

It allows the gastroenterologist to directly examine the intestinal lining and collect small tissue samples called biopsies.

The appearance of inflammation and microscopic biopsy findings help establish the diagnosis and determine disease extent.

Small-Bowel Imaging

Because Crohn’s disease may involve sections of the small intestine that cannot be fully examined during standard colonoscopy, additional imaging may be required.

Depending on the situation, this can include CT enterography, MR enterography or intestinal ultrasound. The 2025 ACG Crohn’s guidance formally recognises intestinal ultrasound as a non-invasive monitoring and diagnostic adjunct alongside CT and MR enterography.

Treatment Has Changed: Symptom Control Is No Longer Enough

This is the most important development in modern IBD care.

Traditionally, treatment often followed a gradual step-up approach.

A patient might start with simpler medicines, move to steroids, try conventional immunosuppressants and reach biologic treatment only after repeated failure.

That approach is changing for patients with more significant disease.

The updated 2025 ACG Crohn’s guideline advises that appropriate patients with moderate-to-severe Crohn’s disease should not necessarily be required to fail conventional medications before receiving advanced therapy.

Modern treatment is increasingly based on the patient’s disease severity and risk rather than making every patient follow exactly the same sequence.

What Does “Treat-to-Target” Mean?

Imagine someone with Crohn’s disease starts treatment.

Three months later, the diarrhoea has stopped.

Under an older symptom-focused approach, that might appear to mean treatment has worked.

But what if significant inflammation remains inside the bowel?

The patient feels better, yet intestinal damage may still continue.

That is why modern IBD management increasingly follows a treat-to-target strategy.

The goal is not merely:

“Do you feel better?”

Doctors may also evaluate whether inflammatory markers have improved and whether the bowel lining itself is healing.

The 2025 ACG guidelines identify endoscopic improvement or mucosal healing as an important therapeutic target in both Crohn’s disease and ulcerative colitis.

Modern Treatment for Ulcerative Colitis

Treatment depends strongly on how much of the colon is affected and whether disease is mild, moderate or severe.

5-ASA Medicines

Aminosalicylates such as mesalamine remain important treatments for many patients with mild-to-moderate ulcerative colitis.

Depending on disease location, they may be given orally, rectally or through a combination approach.

Corticosteroids

Steroids can rapidly reduce inflammation during a significant flare.

But they are not intended to be long-term maintenance therapy.

One major aim of modern UC care is sustained remission without ongoing steroid use because repeated or prolonged steroid exposure carries substantial risks.

Biologic Medicines

Biologic therapies target particular parts of the inflammatory pathway rather than broadly suppressing the entire immune response.

Current options for moderate-to-severe ulcerative colitis can include several different biological classes, such as:

• Anti-TNF therapy
• Vedolizumab
• Ustekinumab
• IL-23 inhibitors

The updated 2025 ACG guideline includes anti-TNF agents, vedolizumab, ustekinumab and IL-23-targeted treatments among advanced therapeutic options.

Oral Targeted Therapies

Not every advanced treatment is an injection or infusion anymore.

Modern ulcerative-colitis management also includes selected oral small-molecule treatments, including JAK inhibitors and S1P receptor modulators for appropriate patients.

Examples appearing in current ACG guidance include upadacitinib and tofacitinib among JAK inhibitors, and ozanimod and etrasimod among S1P modulators.

These medicines have important indications, contraindications and safety considerations, so the choice should be made by an experienced specialist rather than simply selecting the newest therapy.

Modern Treatment for Crohn’s Disease

Crohn’s disease often requires a different strategy because the disease can affect deeper layers of the intestinal wall and develop complications such as strictures and fistulas.

Steroids for Short-Term Control

Corticosteroids may be used to induce remission in selected patients with active disease.

The 2025 ACG guidance strongly emphasises that systemic steroids should be short-term induction therapy rather than long-term maintenance treatment, with transition to a steroid-sparing strategy.

Anti-TNF Therapy

Medicines targeting tumour necrosis factor have transformed treatment for moderate-to-severe Crohn’s disease.

They continue to have an important role, particularly in certain complicated forms of disease. Infliximab remains an important first-line advanced treatment for fistulising Crohn’s disease in current ACG guidance.

Vedolizumab and Ustekinumab

These biologic treatments work through different inflammatory pathways and provide additional options for patients requiring advanced therapy.

Both remain part of the modern therapeutic armamentarium for Crohn’s disease.

IL-23 Targeted Treatment

One major recent development is the expansion of medicines targeting the IL-23 inflammatory pathway.

The 2025 ACG Crohn’s guideline includes IL-23 inhibitors such as risankizumab, guselkumab and mirikizumab among modern treatment options for moderate-to-severe disease.

JAK Inhibitors

The JAK inhibitor upadacitinib has also expanded the availability of oral advanced therapy for Crohn’s disease and is included in current treatment recommendations for appropriate patients.

The expanding range of therapies is good news, but it also makes treatment selection more complex.

Does “Advanced Therapy” Mean the Disease Is Extremely Serious?

Not necessarily.

This is a misconception that can make young patients unnecessarily afraid of biologics.

The use of advanced treatment does not automatically mean that a patient has reached the “last stage” of IBD.

For some patients with moderate-to-severe or high-risk Crohn’s disease, modern guidelines support using effective advanced treatment earlier specifically to improve long-term disease control and reduce the risk of complications.

In other words, biologic treatment should not automatically be seen as something reserved only for when everything else has failed.

How Does a Doctor Choose Between So Many Treatments?

There is no single “best IBD medicine” for everyone.

Treatment selection can depend on:

• Whether the condition is Crohn’s disease or ulcerative colitis
• Disease severity
• Which part of the digestive tract is involved
• Previous treatment
• Fistulas or strictures
• Other medical conditions
• Infection risk
• Pregnancy or family-planning considerations
• Patient preference
• Route of administration
• Medicine availability and affordability

The 2025 ACG Crohn’s guideline specifically stresses individualised therapy selection based on disease phenotype, previous drug exposure, comorbidities and patient preference.

This is one reason copying another IBD patient’s medicines is a bad idea.

Two people can both have Crohn’s disease and still require very different treatment plans.

Can Diet Cure Crohn’s Disease or Ulcerative Colitis?

Diet matters, but claims that one diet can cure all IBD are misleading.

Some dietary strategies may help selected patients, especially in specific situations and under medical and nutritional supervision.

However, current Crohn’s guidance warns that relying on dietary therapy alone should not delay effective treatment in patients with more severe or high-risk disease.

Nutrition is still extremely important because people with active IBD may experience reduced food intake, weight loss or nutrient deficiencies.

The correct question is therefore not:

“Medicine or diet?”

It is:

“What combination of medical treatment, nutrition and monitoring does this individual patient need?”

Can IBD Be Permanently Cured?

At present, Crohn’s disease and ulcerative colitis are generally considered chronic conditions rather than diseases that can reliably be eliminated permanently with medication.

However, modern treatment can achieve remission, sometimes for long periods.

During remission, patients may have little or no symptoms and controlled intestinal inflammation.

The realistic goal is to keep disease controlled, maintain intestinal healing and prevent complications.

For many young patients, that can mean continuing education, careers, relationships, travel and other normal activities rather than organising life around bowel symptoms.

What Happens If IBD Is Left Untreated?

Uncontrolled intestinal inflammation can lead to progressively more serious complications.

Depending on the type of IBD, these can include severe bleeding, malnutrition, intestinal narrowing, obstruction, fistulas, abscesses and the eventual need for surgery.

Long-standing inflammatory disease of the colon can also increase colorectal-cancer risk, which is one reason appropriate disease control and surveillance are important components of long-term IBD care. The current UC guideline specifically identifies prevention of complications, hospitalisation, surgery and cancer among major treatment objectives.

Why Regular Monitoring Matters Even When You Feel Fine

IBD can sometimes remain biologically active despite relatively mild symptoms.

For this reason, modern follow-up may combine:

• Symptoms
• Blood tests
• Faecal calprotectin
• Colonoscopy
• Imaging where appropriate

Current Crohn’s guidance also recommends endoscopic follow-up after surgery because recurrence can appear before severe symptoms develop.

For young patients who may need decades of disease management, preventing repeated cycles of inflammation and damage is particularly important.

When Should You See a Gastroenterologist?

You should consider medical evaluation if you have persistent diarrhoea, recurrent blood in the stool, unexplained weight loss, significant abdominal pain, recurrent urgency, anaemia or bowel symptoms that repeatedly wake you at night.

Blood in the stool, significant weight loss and night-time diarrhoea are particularly important warning signs that deserve medical assessment rather than repeated self-treatment.

For patients seeking IBD treatment in Ahmedabad, DrGastro provides gastroenterology evaluation for small-intestinal and inflammatory bowel disorders, including Crohn’s disease and ulcerative colitis.

Depending on the condition, assessment may include blood and stool testing, colonoscopy, biopsy and appropriate small-bowel evaluation before an individual treatment plan is established.

IBD at 20 or 30 Does Not Have to Control the Next 40 Years

Being diagnosed with Crohn’s disease or ulcerative colitis at a young age can initially sound overwhelming.

But IBD treatment today looks very different from treatment even a decade ago.

Modern care now includes:

better non-invasive monitoring, treat-to-target strategies, biologic medicines, IL-23 therapies, oral small molecules and earlier use of effective advanced treatment for appropriate patients.

The goal is no longer simply to stop diarrhoea for a few weeks.

It is to achieve durable, steroid-free remission, control intestinal inflammation, protect the bowel from progressive damage and allow patients to maintain their quality of life.

For young adults experiencing persistent bowel symptoms, the most important step is therefore not repeatedly changing diets or taking medicines without diagnosis.

It is finding out whether inflammation is actually present and treating it according to its severity.